Why the study?
Does detectable cTnT at very low plasma concentrations predict adverse outcomes in patients with stable chronic heart failure?
Does detectable cTnT at very low plasma concentrations predict adverse outcomes in patients with stable chronic heart failure?
Highly sensitive troponin T assays can detect very low concentrations of cTnT that retain prognostic value for adverse outcomes in stable chronic heart failure.
May aid risk stratification in stable chronic HF; leaves open whether it should guide therapy pending prospective validation.
In this large population of patients with HF, detectable cTnT predicts adverse outcomes in chronic HF. By the highly sensitive assay, troponin T retains a prognostic value at previously undetectable concentrations.
No takes yet. Share an insight, caveat, or question.
Latini et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: